JPMorgan Analysts Kasimov, Fye and Rama will host a conference call with CEO Clay Siegall on June 12 at 11 am.
It sounds great on the business sense to me that SGEN will now have access to the CAR-T/TCR/TIL technology to fight cancer. It may be a combination of ADC/CAR-T techology cancer therapy.
Please share with us your insight into this collaboration.
This is the D..est question of the year. Who is in his/her right mind to know SGEN to be bought out to answer your question? The only one who doesn't know anything will say..."I don't think so"..
As always, thanks a lot for your insights. Here is another link the a more uodated info about the ongoing clinical trial of DCVax.
Do you have a chance to read the comments of UCLA chair of Neurosurgery on NWBO DCVax-L. Here is a quote of what he wrote:
The UCLA Brain Tumor Program continues to shine as a beacon of hope, carrying a record of patients with brain tumors living longer than patients treated at any other hospital. Our personalized brain cancer vaccine, DCVax, is the first of its kind and is currently in Phase III clinical trials in 46 centers throughout America. It is on the road to FDA approval as well as clinical trials throughout Europe. Using this vaccine, we are harnessing the patient’s immune system, genetics, pathology, brain mapping and a wide database of bioinformatics to optimize outcomes.
It looks like he is impressed with the product himself. For more info, please read at:
How deep in the money and what the expiry date did you buy your calls?
I just want to learn your way of doing this.
The news is that SGEN pipeline is great and Baker Bros were so excited about the future of SGEN so they loaded up approximately 5.4 mil shares to the total holding of 27.86 million shares.
I can see that SGEN will be a great investment in the next couple years pending 3 phase 3 results from Adcetris and its pipeline.